Introduction: One of the most common side effects during vincristine (VCR) use is the establishment of VCR–induced peripheral neuropathy (VIPN). Among several risk factors that can influence the development of VIPN, such as cumulative dose and patient’s age, sex, ethnicity, and genetic variants, this review is focused on the genetic variability. Areas covered: A literature research was performed firstly using the following PubMed search string ((((CIPN OR (vincristine AND neurotoxicity OR (vincristine AND neuropathy))) AND (polymorphisms OR (genetic variants OR (genetic factors OR (genetic profile OR (pharmacogenetics OR (genome-wide OR (genetic risk OR (expression genotype))))))))))) but also other relevant papers cited by the selected articles were included. Based on the obtained results, we identified two main categories of genes: genes involved in pharmacokinetics (genes related to metabolism and transport) or pharmacodynamics (genes related to mechanism of action) of VCR. Expert opinion: Despite several clinical retrospective studies investigating the possible correlations between patient genotype and VIPN onset, contrasting and inconsistent results are reported. In conclusion, given the clinical relevance of VIPN, further and more focused research would be fundamental in order to identify genetic variants able to predict its development and to allow a safer management of treated patients.

Pozzi, E., Fumagalli, G., Chiorazzi, A., Canta, A., & Cavaletti, G. (2021). Genetic factors influencing the development of vincristine-induced neurotoxicity. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 17(2), 215-226 [10.1080/17425255.2021.1855141].

Genetic factors influencing the development of vincristine-induced neurotoxicity

Pozzi E.;Fumagalli G.
;
Chiorazzi A.;Canta A.;Cavaletti G.
2021

Abstract

Introduction: One of the most common side effects during vincristine (VCR) use is the establishment of VCR–induced peripheral neuropathy (VIPN). Among several risk factors that can influence the development of VIPN, such as cumulative dose and patient’s age, sex, ethnicity, and genetic variants, this review is focused on the genetic variability. Areas covered: A literature research was performed firstly using the following PubMed search string ((((CIPN OR (vincristine AND neurotoxicity OR (vincristine AND neuropathy))) AND (polymorphisms OR (genetic variants OR (genetic factors OR (genetic profile OR (pharmacogenetics OR (genome-wide OR (genetic risk OR (expression genotype))))))))))) but also other relevant papers cited by the selected articles were included. Based on the obtained results, we identified two main categories of genes: genes involved in pharmacokinetics (genes related to metabolism and transport) or pharmacodynamics (genes related to mechanism of action) of VCR. Expert opinion: Despite several clinical retrospective studies investigating the possible correlations between patient genotype and VIPN onset, contrasting and inconsistent results are reported. In conclusion, given the clinical relevance of VIPN, further and more focused research would be fundamental in order to identify genetic variants able to predict its development and to allow a safer management of treated patients.
No
Articolo in rivista - Review Essay
Scientifica
Neurotoxicity; pharmacogenetic; polymorphisms; risk factors; vincristine;
English
Pozzi, E., Fumagalli, G., Chiorazzi, A., Canta, A., & Cavaletti, G. (2021). Genetic factors influencing the development of vincristine-induced neurotoxicity. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 17(2), 215-226 [10.1080/17425255.2021.1855141].
Pozzi, E; Fumagalli, G; Chiorazzi, A; Canta, A; Cavaletti, G
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/298478
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact